EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSAOCG00000003652
Gene Symbol: ATP1B2
3 Cross references
193 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSAOCG00000002568
Gene Symbol: ATP1B3
3 Cross references
229 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSAOCG00000019257
Gene Symbol: ATR
3 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSAOCG00000007215
Gene Symbol: AXL
4 Cross references
188 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSAOCG00000010835
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSAOCG00000009944
Gene Symbol: BCL2
3 Cross references
172 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSAOCG00000024114
Gene Symbol: BCL2L1
3 Cross references
229 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSAOCG00000020533
Gene Symbol: BCL2L1
3 Cross references
216 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSAOCG00000022528
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSAOCG00000000229
Gene Symbol: BCR
3 Cross references
203 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSAOCG00000011496
Gene Symbol: LOC111564839
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSAOCG00000020280
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).